Evidence map›Paper›PMID 11175741›Full record

ArticleNature cell biology2001

Repression of origin assembly in metaphase depends on inhibition of RLF-B/Cdt1 by geminin.

S Tada, A Li, D Maiorano, M Méchali, J J Blow

Abstract read
In one paragraph

Article in Nature cell biology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 208 papers.

0numbers the graph read from it
0cells of the map it votes in
208citing papers in PubMed
16.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

208 citing papers in PubMed, 449 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. CDK4/6 activity is required during GScience (New York, N.Y.) · 2024
    Article
  8. Multiple pathways for licensing human replication origins.bioRxiv : the preprint server for biology · 2024
    Article
  9. Article
  10. Article
  11. Critical DNA damaging pathways in tumorigenesis.Seminars in cancer biology · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Cell cycle (Georgetown, Tex.) · 2019
    Article
  19. Review
  20. Article

148 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

S TadaCRC Chromosome Replication Research Group, Wellcome Trust Biocentre, Dow Street University of Dundee, Dundee DD1 5EH, UK.
A Li
D Maiorano
M Méchali
J J Blow
Centre National de la Recherche Scientifique · FRUniversity of Dundee · GBWellcome Trust · GB

Funding

Cancer Research UK A2335
6 · The paper itself

Abstract

Eukaryotic replication origins are 'licensed' for replication early in the cell cycle by loading Mcm(2-7) proteins. As chromatin replicates, Mcm(2-7) are removed, thus preventing the origin from firing again. Here we report the purification of the RLF-B component of the licensing system and show that it corresponds to Cdt1. RLF-B/Cdt1 was inhibited by geminin, a protein that is degraded during late mitosis. Immunodepletion of geminin from metaphase extracts allowed them to assemble licensed replication origins. Inhibition of CDKs in metaphase stimulated origin assembly only after the depletion of geminin. These experiments suggest that geminin-mediated inhibition of RLF-B/Cdt1 is essential for repressing origin assembly late in the cell cycle of higher eukaryotes.

Indexed as

Xenopus ProteinsAnimalsCell Cycle ProteinsCell NucleusChromatinDNA-Binding ProteinsDNA ReplicationGemininImmunoblottingMetaphaseMinichromosome Maintenance Complex Component 7Models, BiologicalNuclear ProteinsOocytesRecombinant ProteinsReplication OriginCdt1 protein, XenopusCell Cycle ProteinsChromatinDNA-Binding ProteinsGemininGMNN protein, XenopusMcm7 protein, XenopusMinichromosome Maintenance Complex Component 7Nuclear ProteinsRecombinant ProteinsXenopus Proteins

Identifiers

PMID11175741
PMCPMC3605706
OpenAlexW2128056082

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.